31 / 43
31
•
Retrospective study of
c
etuximab and paclitaxel in R/M SCCHN*
•
Pajares Bernad I, et al. ESMO 2016 (Abstract 991P)
Image courtesy of Arthur Shlain via the Noun project
•
*QW paclitaxel + cetuximab is an off-label treatment in R/M SCCHN
•
QW, once weekly
Retrospective analysis
of clinical records
QW paclitaxel
(80mg/m
2
)
Cetuximab
(400/250mg/m
2
)
Jan
2008
Patients recruited between
January 2008 and July 2014
Unselected patients with
R/M SCCHN treated with
weekly paclitaxel +
cetuximab*
Endpoints: Measured response, OS and PFS
+
Patient characteristics (N=148)
Median age, years (range)
62 (38–87)
Male, %
90
Location of primary tumor, %
Larynx
Oral cavity
Oropharynx
Hypopharynx
Other
30
30
18
7
16
Tumor stage, %
Unresectable
Metastatic
Unresectable and metastatic
68
6
26
Previous platinum treatment, %
70
ECOG PS, %
0–1
82
Jul
2014